Abstract: A dimming controller is coupled to receive an out-source current from a dimming interface for each LED driver connected thereto. Based on the out-source current received, the controller can estimate the number of connected LED drivers. When the LED driver(s) are determined to be on based on the received out-source current, the dimming controller generates and transmits a dimming control voltage. The dimming controller is programmable with relationships between the dimming control voltage and operational parameters for the certain type of LED driver and the certain type of LED load. The dimming controller then estimates the power characteristics (e.g., the input power and the output power) of the LED driver and associated LED load based on the programmed relationships. Power characteristics can accordingly be reported to the customer via a dimming controller without requiring specifically designed power measuring devices. Driver failure in the group can be reported in real time.

Abstract: The present disclosure is generally related to transformed host cells and their use for the production of branched-chain acyl-ACPs, branched-chain acyl-ACP-derived chemicals and fuels, branched-chain fatty acids and producing branched-chain fatty acid-derived chemicals and fuels. More particularly, disclosed herein are transformed host cells and methods for producing branched-chain acyl-ACPs and branched-chain fatty acids in high titer and high percentages. Also disclosed are methods for producing specific branched-chain fatty acid species and producing branched-chain fatty acid-derived chemicals and fuels such as, for example, branched-chain alcohols and branched-chain fatty acid ethyl esters.

Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Abstract: Described here are systems and methods for producing high-resolution three-dimensional (“3D”) relaxation parameter maps by calibrating high-resolution 3D magnetic resonance images. As one example, high-resolution longitudinal relaxation time (“T1”) maps can be generated based on images acquired using a T1-weighted pulse sequence, and as another example high-resolution transverse relaxation time (“T2”) maps can be generated based on images acquired using a T2-weighted pulse sequence. The high-resolution images can be calibrated, for example, using a lower resolution single slice relaxation parameter map. The methods described here utilize high-resolution 3D scans and low-resolution relaxation parameter maps that are commonly available on MRI systems. The calibration is a post-processing step used to create the high-resolution 3D relaxation parameter maps from these two types of scans.

Abstract: Pulse sequences for an MRI apparatus can provide improved quantitative relaxometry in liver and other tissues. Relaxation parameters such as T1rho or T2 (or both at once) can be measured. The pulse sequence can include a magnetization preparation pulse sequence and an acquisition pulse sequence including a fast spin echo (FSE) pulse sequence. Flip angles and echo time for the FSE pulse sequence can be chosen to optimize image quality without affecting the quantification of a relaxation parameter. Additional pulse sequences, e.g., for enhanced blood suppression and/or fat suppression can be incorporated. The acquisition pulse sequence can have a duration that allows data for a single slice image to be acquired during a breath-hold.

Abstract: A cyber-physical system (CPS) pressure based sensing system and methods for assessing stance or mobility of a test subject standing or moving are provided. The CPS pressure based sensing system can include at least one piezoresistive transducer configured to obtain a plurality of measurements with respect to the stance or movements of the test subject, and a data analyzer configured to determine patterns of the stance or movement by performing machine learning classification on the plurality of measurements obtained by the at least one piezoresistive transducer.

Abstract: A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.

Abstract: The present disclosure relates to a method and an apparatus for coding data to be transmitted in a communication system, and more particularly, to a method and an apparatus for generating a sequence for a polar code for use in a communication system and a method and an apparatus for transmitting data using the same. The method according to the embodiment of the present disclosure is a method for transmitting data using a polar code including: generating a single polar code sequence for transmitting the data; coding the data using the generated single polar code sequence; and transmitting the polar-coded data.

Abstract: A coupled via structure includes a plate via penetrating through an board body and having first and second plates spaced apart from each other by a first gap distance, a contact pad connected to the plate via on a surface of the board body and having first and second contacts connected to the first and second plates, respectively, and a connection line connected to the contact pad on the surface of the board body and having first and second lines connected to the first and second contacts, respectively, and spaced apart from the first line by a second gap distance. Accordingly, the deviation of the characteristic impedance is reduced (or, alternatively, minimized) between the coupled via structure and the coupled signal line.

Abstract: Porcine pestivirus designated herein as atypical porcine pestivirus (“APPV”) (Genbank accession no. KR011347.1). Immunogenic compositions to induce an immune response against porcine pestivirus infection in a pig are described, which APPV antigenic agents (e.g., isolated whole virus, derivatives thereof, functional fragments thereof, and combinations of the foregoing). Methods of vaccinating against porcine pestivirus infection using the immunogenic compositions are also described. The methods can be also applied for clinical research and/or study, including diagnostic methods for detecting pestivirus infection using monoclonal antibodies specifically binding to APPV epitopes.

Abstract: The purpose of the present invention is to enable, even in an endoscopic operation, an operation upon a specific operation site while monitoring the overall surgical site, such as an organ. An artificial magnetic field is generated such that a surgical site of a patient is positioned within a generated three-dimensional artificial magnetic field space. A plurality of magnetic sensors are respectively mounted in a plurality of predetermined locations of the surgical site of the patient. Data of a 3-D image of the surgical site and position information of the mounting locations of the magnetic sensors with respect to the surgical site are stored in a storage unit as position information of the mounting locations with respect to the 3-D image of the surgical site.

Abstract: The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject susceptible to formation of an adhesion to an agent having iron chelation and/or antioxidant activity, thereby reducing adhesions in the subject.

Abstract: The present invention provides an oxide-dispersed metal porous body including a porous metal framework, and oxide particles carried in the metal framework.

Abstract: Disclosed herein are methods of detecting or making a risk evaluation of a cancer that has a mutated PREX2 expressed thereon. The cancer may be a primary cancer, a metastatic cancer or a recurrent cancer. According to the embodiment of the present disclosure, the mutation is G258V, S1113R, E1346D or K400fs. Also disclosed herein are methods of treating the subject in need thereof.

Abstract: A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and/or infiltration into target tissue and/or proliferation in the tissue of eosinophils and/or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage.

Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.

Abstract: The present disclosure is directed to an anatomical model and methods for using the same. The anatomical model of the present disclosure includes a plurality of simulated bodily structures that emulate the naturally occurring structures (e.g., organs, bones, and tissue) of the human body. The anatomical model of the present disclosure can be used to simulate clinical conditions observed in infant subjects and carry out medical procedures and interventions commonly practiced by clinicians under real-life conditions.

Abstract: A luminescent materials including donor-acceptor compounds with a nitrogen containing donor connected to the 1-position of a carbazole and triazene acceptor connected at the 9-position is disclosed.

Abstract: A multi-layer coating that allows arrest of contaminant infiltration includes at least one layer that is not very reactive to an infiltrating reactive species, and at least one highly reactive ceramic layer (HRC layer) containing materials that react to slow or arrest contaminant infiltration.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutam